Former DeepMind intern launches Atomic AI to 'parse' RNA structure for new small molecules
Another artificial intelligence startup has entered the drug discovery field, this time on a mission to fuel new RNA small molecules.
Atomic AI revealed a $35 million Series A Wednesday morning to boost its computational and wet lab work. The 14-employee startup will use the proceeds to continue building out its so-called PARSE platform, which is focused on predicting the 3D structure of RNA.
“There are a number of RNA transcripts of interest that we want to drug with small molecules, specifically, and a major issue across the field is that it is hard to get selective functional small molecule binders to those transcripts,” CEO and founder Raphael Townshend told Endpoints News in a preview. “And oftentimes, the mechanism of action is decreasing the amount of protein being expressed.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.